Press Release: SNDL Reports Third Quarter 2026 Financial and Operational Results

Dow Jones10-27

EDMONTON, Alberta, Oct. 27, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ/CSE: SNDL) ("SNDL" or the "Company") reported its financial and operational results for the third quarter ended September 30, 2026. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated.

SNDL has also posted a supplemental investor presentation on its website, found at https://sndl.com.

The Company will hold a conference call and webcast presentation at 10:00 a.m. EDT (8:00 a.m. MDT) on Tuesday, October 27, 2026. The conference call details can be found below.

MANAGEMENT HIGHLIGHTS

   -- Net revenue for the third quarter of 2026 was $238.0 million, 
      representing a -2.5% decrease compared with the same period of the prior 
      year. Cannabis Retail revenue increased by 0.7%, while Liquor Retail and 
      Cannabis Operations revenue declined by -3.3% and -27.7%, respectively. 
 
   -- Gross profit of $57.9 million for the third quarter of 2026 represents a 
      decline of $(6.3) million, or -9.8%, compared with the same period of the 
      prior year. 
 
   -- Gross margin (1) was 24.3% in the third quarter of 2026, a decrease of 
      2.0 percentage points compared with the same period of the prior year, 
      primarily reflecting weak performance of Cannabis Operations. Both retail 
      segments delivered strong margin expansion and reached new quarterly 
      records. 
 
   -- Operating loss was $(48.3) million for the third quarter of 2026, 
      reflecting a $52 million non-cash goodwill impairment charge related to 
      the Cannabis Operations segment. 
 
   -- Adj. operating income (1), which excludes impairment charges and 
      restructuring costs, returned to positive territory at $5.2 million, an 
      improvement of $14.8 million compared with the same period of the prior 
      year. 
 
   -- Cash flow was $(50.7) million, reflecting $60.8 million of strategic 
      investments in the U.S. and $10.0 million of additional share repurchases, 
      consistent with our capital allocation priorities. 
 
   -- Free cash flow (1) reached a new quarterly record of $20.0 million in the 
      third quarter of 2026, an increase of $3.3 million, or 19.5%, compared 
      with the same period of the prior year, including a $10.6 million benefit 
      associated with the initial unwinding of the Company's captive insurance 
      arrangement. 

"Our third quarter results demonstrate improvement in SNDL's underlying financial performance, including positive adjusted operating income and record quarterly free cash flow generation," said Zach George, Chief Executive Officer of SNDL. "Cannabis Retail delivered record quarterly revenue and gross margin, Liquor Retail also reached a new record quarterly gross margin, and our Investments segment benefited from improved results from equity-accounted investees."

"Cannabis Operations remained below expectations and recorded a non-cash impairment. While the quarter was impacted by inventory issues arising from the first half, we are taking decisive action to simplify the portfolio, reduce costs and concentrate resources on product categories where SNDL's manufacturing capabilities, distribution reach and retail insights can support sustainable returns. The benefits of the actions taken during the quarter are expected to begin contributing to results in the fourth quarter. In addition to these immediate actions, the Company is initiating a strategic review of the Cannabis Operations segment to assess opportunities to improve its financial performance. The review will consider a range of strategic and operational alternatives, from potential asset divestitures to larger productivity initiatives."

"The completion of the restructuring of Surterra Holdings, Inc. ("Parallel") in July of this year, which reduced its debt burden by approximately US$842 million, and the subsequent rights offering, which increased our indirect equity ownership from approximately 67% to 92%, represent important steps in resetting Parallel's capital structure and providing liquidity to support inventory, product availability and critical supply-chain infrastructure. SNDL-funded investments by SunStream Bancorp Inc. ("SunStream") in a new cultivation facility in Gainesville, Florida, are expected to enhance Parallel's cost structure. We are excited by the opportunity presented by our investment in Parallel and are actively exploring the feasibility of transitioning our indirect economic exposure to direct ownership and consolidation of qualifying U.S. medical cannabis operations, subject to applicable legal, regulatory, accounting and Nasdaq requirements."

"We are encouraged by the progress made toward resolving the regulatory matters involving the Alcohol and Gaming Commission of Ontario ("AGCO"), which we expect will provide greater clarity for the Ontario franchise retail operations and future development opportunities, as further detailed later in this document and in the Q3 2026 Earnings Call presentation."

"Across SNDL, our priorities remain disciplined capital allocation, improved operating performance and long-term value creation for shareholders. We have demonstrated that commitment through significant share repurchases, and we intend to remain aggressive when we believe the opportunity to acquire our shares represents an attractive use of capital. The recently announced potential $50 million substantial issuer bid ("SIB") is a further step toward accelerating capital returns and reducing our outstanding share count," concluded Zach George.

TOTAL COMPANY HIGHLIGHTS

 
                Three months ended September 30          Nine months ended September 30 
($000s)           2026       2025        % Change        2026         2025        % Change 
------------  --------      -------      --------      --------      -------      -------- 
IFRS 
Financial 
Measures 
------------ 
Net revenue    237,994      244,219          -2.5%      669,666      693,902          -3.5% 
Gross profit    57,886       64,177          -9.8%      167,047      188,419         -11.3% 
Operating 
 income 
 (loss)        (48,317)     (11,050)       -337.3%      (65,272)     (18,100)       -260.6% 
Change in 
 cash and 
 cash 
 equivalents   (50,729)      32,357        -256.8%     (107,622)      22,222        -584.3% 
 
Non-IFRS 
Financial 
Measures 
(1) 
------------ 
Gross margin      24.3%        26.3%         -2.0  pp      24.9%        27.2%         -2.2  pp 
Adjusted 
 operating 
 income 
 (loss)          5,249       (9,512)        155.2%      (10,675)     (12,713)         16.0% 
Free cash 
 flow           19,954       16,692          19.5%        5,692        7,733         -26.4% 
 
 

(1) Gross Margin is a supplementary financial measure calculated by dividing Gross Profit by Net Revenue. Adjusted operating income (loss) and Free Cash Flow are specified financial measures that do not have standardized meanings under IFRS and therefore may not be comparable to similar measures reported by other companies. See "Non-IFRS Measures" section below for further information.

BUSINESS SEGMENT HIGHLIGHTS

SNDL operates and reports its business through four segments: Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments. Additionally, a consolidated total for Cannabis is presented, encompassing the combined results of the two Cannabis segments, along with the revenue elimination associated with the Cannabis Operations sales to the provincial boards that are expected to be subsequently repurchased by the Company's licensed retail subsidiaries for resale. Corporate and shared service expenses are reported as "Corporate".

 
                  Three months ended September       Nine months ended September 
                               30                                 30 
($000s)               2026   2025(2)   % Change       2026     2025(2)   % Change 
Net Revenue 
---------------- 
   Cannabis 
    Retail          85,605    85,021        0.7%     246,154   246,960       -0.3% 
   Cannabis 
    Operations      27,040    37,389      -27.7%      88,704   107,544      -17.5% 
   Intersegment 
    Eliminations    (9,425)  (17,579)      46.4%     (38,757)  (51,391)      24.6% 
Total Cannabis     103,220   104,831       -1.5%     296,101   303,113       -2.3% 
Liquor Retail      134,774   139,388       -3.3%     373,565   390,789       -4.4% 
Investments             --        --        0.0%          --        --        0.0% 
Total              237,994   244,219       -2.5%     669,666   693,902       -3.5% 
 
Operating Income 
---------------- 
   Cannabis 
    Retail           5,244     5,047        3.9%       9,328    10,557      -11.6% 
   Cannabis 
    Operations     (64,693)  (10,882)    -494.5%     (80,836)  (20,186)    -300.5% 
Total Cannabis     (59,449)   (5,835)    -918.8%     (71,508)   (9,629)    -642.6% 
Liquor Retail        6,035     6,591       -8.4%       5,899    10,884      -45.8% 
Investments          7,861     1,543      409.5%       8,340     1,775      369.9% 
Corporate           (2,764)  (13,349)      79.3%      (8,003)  (21,130)      62.1% 
Total              (48,317)  (11,050)    -337.3%     (65,272)  (18,100)    -260.6% 
 
Adjusted 
Operating 
Income 
---------------- 
   Cannabis 
    Retail           5,284     5,047        4.7%       9,403    10,557      -10.9% 
   Cannabis 
    Operations     (11,391)  (10,220)     -11.5%     (27,303)  (16,258)     -67.9% 
Total Cannabis      (6,107)   (5,173)     -18.1%     (17,900)   (5,701)    -214.0% 
Liquor Retail        6,037     6,591       -8.4%       6,126    10,884      -43.7% 
Investments          7,861     1,543      409.5%       8,340     1,775      369.9% 
Corporate           (2,542)  (12,473)      79.6%      (7,241)  (19,671)      63.2% 
Total                5,249    (9,512)     155.2%     (10,675)  (12,713)      16.0% 
 
 

(2) In 2026, the Company began allocating applicable direct and indirect overhead costs from the corporate segment to each individual operating segment all categorized within general and administrative expenses. The Company has recast the comparative period to illustrate the impact of these allocations had they been done during the prior period, as documented in the condensed interim Financial Statements.

Liquor Retail

SNDL is Canada's largest private-sector liquor retailer, operating as of October 26, 2026 in 165 locations, predominantly in Alberta, under its three retail banners: "Wine and Beyond" (16), "Liquor Depot" (19), and "Ace Liquor" (130).

 
              Three months ended September 30          Nine months ended September 30 
($000s)         2026       2025        % Change       2026         2025        % Change 
----------  --------      -------      --------      -------      -------      -------- 
Net revenue  134,774      139,388          -3.3%     373,565      390,789          -4.4% 
Gross 
 profit       36,390       36,704          -0.9%      96,828      100,993          -4.1% 
Gross 
 margin         27.0%        26.3%          0.7  pp     25.9%        25.8%          0.1  pp 
Operating 
 income        6,035        6,591          -8.4%       5,899       10,884         -45.8% 
Adjusted 
 operating 
 income        6,037        6,591          -8.4%       6,126       10,884         -43.7% 
 
 
   -- Net revenue for Liquor Retail continued to decline year over year in the 
      third quarter of 2026, although at a slightly better rate than in 
      previous quarters. Persistent softness in market demand continued to 
      affect same-store sales(3), which decreased by -6.0% compared with the 
      same period in the prior year. 
 
   -- Operating income declined year over year, driven by lower revenue, 
      increased promotional support, and higher SG&A expenses associated with 
      the recent Wine & Beyond store openings, partly offset by strong gross 
      margin expansion, which reached a new quarterly record. 

(3) Same-store sales is a specified financial measure that does not have standardized meanings under IFRS and therefore may not be comparable to similar measures used by other companies. See "Non-IFRS Measures" section below for further information.

Cannabis Retail

SNDL is one of Canada's largest private-sector cannabis retailers, operating as of October 26, 2026 in 193 locations under two retail banners: "Value Buds" (133) and "Spiritleaf" (60, of which 4 are corporate stores and 56 are franchise stores). The Company's Cannabis Retail strategy is based on several pillars, including high-quality store locations, a broad product assortment and differentiated customer experiences. Using data and insights from a large volume of monthly transactions enables SNDL to leverage technology and analytics to inform and improve its retail strategy.

 
             Three months ended September 30         Nine months ended September 30 
($000s)        2026       2025       % Change       2026         2025        % Change 
----------  -------      ------      --------      -------      -------      -------- 
Net revenue  85,605      85,021           0.7%     246,154      246,960          -0.3% 
Gross 
 profit      23,118      22,465           2.9%      65,472       63,974           2.3% 
Gross 
 margin        27.0%       26.4%          0.6  pp     26.6%        25.9%          0.7  pp 
Operating 
 income       5,244       5,047           3.9%       9,328       10,557         -11.6% 
Adjusted 
 operating 
 income       5,284       5,047           4.7%       9,403       10,557         -10.9% 
 
 
   -- Net revenue for Cannabis Retail returned to growth in the third quarter 
      compared with the same period of the prior year, consistent with the 
      previously anticipated inflection point, and reached a new quarterly 
      record. Market contraction in our largest provinces (ON, AB) contributed 
      to a -3.8% decline in same-store sales. This decline was partially offset 
      by incremental revenue from new stores and Value Buds store conversions. 
 
   -- Operating income increased compared with the same period of the prior 
      year, primarily driven by gross margin expansion, which reached a new 
      quarterly record, despite lapping a larger impairment reversal recorded 
      in the third quarter of 2025. 
 
   -- Subject to completion of definitive documentation and payment of a 
      $200,000 monetary penalty, the anticipated resolution of the regulatory 
      matters involving the AGCO is expected to allow the Value Buds franchise 
      network to resume growth in Ontario following a pause of more than a year 
      during the regulatory review. While the contemplated structure is 
      expected to result in the deconsolidation of the Ontario retail 
      operations from SNDL's financial statements, we expect the overall 
      commercial arrangements to substantially preserve SNDL's net economics 
      associated with these franchise locations, without retaining control over 
      the retail operations in the province. 

Cannabis Operations

SNDL has a diverse brand portfolio from value to premium, emphasizing premium inhalable formats and a full suite of 2.0 products. With enhanced procurement capabilities and plans to continue evolving toward a cost-effective cultivation and manufacturing operation, the Cannabis Operations segment is a key enabler of SNDL's vertical integration strategy.

 
              Three months ended September 30          Nine months ended September 30 
($000s)         2026       2025        % Change       2026         2025        % Change 
----------  --------      -------      --------      -------      -------      -------- 
Net revenue   27,040       37,389         -27.7%      88,704      107,544         -17.5% 
Gross 
 profit       (1,622)       5,008        -132.4%       4,747       23,452         -79.8% 
Gross 
 margin         -6.0%        13.4%        -19.4  pp      5.4%        21.8%        -16.5  pp 
Operating 
 income 
 (loss)      (64,693)     (10,882)       -494.5%     (80,836)     (20,186)       -300.5% 
Adjusted 
 operating 
 income 
 (loss)      (11,391)     (10,220)        -11.5%     (27,303)     (16,258)        -67.9% 
 
 
   -- Our Cannabis Operations results remain below our expectations, and we are 
      moving aggressively to reshape the segment into a more focused and 
      efficient business. Most of the revenue decline in the third quarter was 
      attributable to our exit from the unprofitable domestic dried flower 
      category and our increased focus on higher-value products. 
 
   -- Profitability was impacted by a $52 million non-cash goodwill impairment 
      reflecting current business trends, as well as $6 million in other 
      impacts, mostly driven by inventory adjustments related to the exit from 
      the dried flower category and Jeeter cost variances. During the third 
      quarter, we took decisive actions to reduce manufacturing costs and other 
      operating expenses, particularly at our Kelowna manufacturing facility, 
      including a reduction of more than 30% of the workforce at the site. The 
      P&L benefits of these cost reductions are expected to begin contributing 
      to results in the fourth quarter. 

Investments

   -- As of September 30, 2026, the Company's portfolio of cannabis-related 
      investments had a carrying value of $485.2 million, including $467.7 
      million to SunStream Bancorp Inc. ("SunStream"). This carrying value was 
      increased by $70.0 million during the third quarter of 2026, primarily 
      driven by additional contributions to fund the buildout of the 
      Gainesville, Florida cultivation facility, SNDL's participation in 
      Parallel's rights offering, and the purchase of an incremental portion of 
      Parallel's debt. 
 
   -- On July 27, 2026, the restructuring of Parallel was completed, providing 
      SNDL with indirect majority economic exposure to the company. During the 
      third quarter, SNDL participated in a Parallel rights offering, while 
      other minority holders declined to participate, increasing SNDL's 
      indirect equity interest from approximately 67% to approximately 92%. 
      SNDL continues to evaluate a pathway to directly own and consolidate 
      Parallel's U.S. medical cannabis operations while maintaining compliance 
      with the applicable Nasdaq requirements. Consistent with recent 
      public-market precedents, SNDL is evaluating structures that distinguish 
      medical cannabis operations from adult-use exposure, with the latter 
      expected to remain outside SNDL's consolidated operations. The Company is 
      actively advancing this work and expects to provide further clarity as 
      the structure and timing are finalized, subject to applicable legal, 
      regulatory, accounting and Nasdaq requirements. 
 
   -- Following the completion of Parallel's restructuring, SNDL also financed 
      SunStream's purchase of an additional portion of Parallel's takeback debt 
      at 75% of face value, increasing SunStream's debt ownership from 39.4% to 
      69.4%. 
 
   -- The Investments segment generated $7.9 million of operating income during 
      the third quarter of 2026, including $6.9 million from SNDL's share of 
      profit from SunStream's equity-accounted investees, primarily reflecting 
      an increase in the valuation of Parallel. 
 
   -- The previously disclosed restructuring process relating to Skymint 
      continues. On April 1, 2026, the Michigan Supreme Court agreed to hear 
      oral argument on applications for leave to appeal. The Court has not 
      reached a decision on the merits. Timing and outcomes remain uncertain 
      and are subject to court process and other factors. 
 
   -- On April 23, 2026, the United States Department of Justice and the United 
      States Drug Enforcement Administration issued an order placing Food and 
      Drug Administration-approved cannabis products and qualifying 
      state-regulated medical cannabis in Schedule III of the United States 
      Controlled Substances Act, while initiating an expedited administrative 
      process to consider the broader rescheduling of cannabis, including 
      adult-use cannabis, from Schedule I to Schedule III. The administrative 
      hearing concluded in July 2026, with a final determination on broader 
      rescheduling still pending. 

Equity Position

   -- $617.8 million of unrestricted cash, marketable securities and 
      investments, including investments in equity-accounted investees, and no 
      outstanding debt at September 30, 2026, resulting in a net book value of 
      $1.0 billion. 
 
   -- During the third quarter of 2026, the Company purchased for cancellation 
      5,431,300 common shares at a weighted average price, excluding 
      commissions, of US$1.31 per share. Year-to-date through October 22, 2026, 
      the Company had purchased for cancellation 23,088,153 common shares, 
      resulting in 243,320,644 common shares outstanding. 
 
   -- As recently communicated, the Company's Board of Directors has directed 
      management to pursue a possible substantial issuer bid ("SIB") for an 
      aggregate purchase price of up to C$50 million and at a price per share 
      not exceeding C$1.92 (US$1.35). If completed and fully subscribed at the 
      maximum price, the SIB could reduce the Company's common shares 
      outstanding by more than an additional 10%. SNDL will continue to 
      evaluate opportunities to repurchase shares where management believes 
      doing so is in the best interests of SNDL and its shareholders. In this 
      context, and subject to approval by SNDL's Board of Directors, we expect 
      to proceed with the renewal of the share repurchase program upon its 
      expiration on November 20, 2026, supported by continued free cash flow 
      and potential targeted asset sales, including non-core real estate and 
      other operating assets. 

This press release is intended to be read in conjunction with the Company's condensed consolidated interim financial statements and the notes thereto for the three and nine months ended September 30, 2026, and the accompanying Management's Discussion and Analysis. These documents are available under the Company's profile on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov/edgar.shtml.

CONFERENCE CALL

The Company will hold a conference call and webcast presentation at 10:00 a.m. EDT (8:00 a.m. MDT) on Tuesday, October 27, 2026.

WEBCAST ACCESS

To access the live webcast of the call, please visit the following link:

https://edge.media-server.com/mmc/p/wcotys5n

REPLAY

A replay of the webcast will be available at https://sndl.com/financials/quarterly-results/default.aspx

ABOUT SNDL INC.

SNDL Inc. (NASDAQ: SNDL, CSE: SNDL), through its wholly owned subsidiaries, is one of the largest vertically integrated cannabis companies and the largest private-sector liquor and cannabis retailer in Canada, with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, and Spiritleaf. With products available in licensed cannabis retail locations nationally, SNDL's consumer-facing cannabis brands include Top Leaf, Contraband, Palmetto, Bon Jak, La Plogue, Versus, Value Buds, Grasslands, Vacay, Pearls by Grön, No Future and Bhang Chocolate. SNDL's investment portfolio seeks to deploy strategic capital through direct and indirect investments and partnerships throughout the North American cannabis industry. For more information, please visit www.sndl.com

For more information:

Tomas Bottger

Investor Relations, SNDL Inc.

O: 1.587.327.2017

E: investors@sndl.com

Forward-Looking Information Cautionary Statement

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"), including, but not limited to, statements regarding the Company's operational goals, plans and key priorities, the strategic review of the Cannabis Operations segment, including its scope, potential alternatives and outcomes, and the expected benefits of any actions resulting from the review, the Company's ability to deploy capital and the expected benefits thereof, expectations related to the Jeeter contract, the growth opportunities available to SNDL and the expected benefits thereof, expectations with respect to the 1CM transaction, including the satisfaction of certain regulatory approvals, the progress of the Sunstream restructurings, expectations with respect to the Skymint and Parallel restructuring processes, the feasibility, structure, timing and expectations related to the Company obtaining direct ownership and control of, and consolidating, qualifying U.S. medical cannabis operations of Parallel, SNDL's corporate restructuring program, including the timing to conclude the restructuring and expected benefits thereof, the expected benefits of the enterprise resource planning ("ERP") system consolidation, SNDL's ability to recover the senior secured notes held in Cannabist, the timing and expected impact of reclassifying cannabis from Schedule I to Schedule III under the United States Controlled Substances Act, the Company's retail strategy, and any other potential forms of shareholder value creation. Forward-looking statements are frequently characterized by words such as "aim", "anticipate", "assume", "believe", "contemplate", "continue", "could", "due", "estimate", "expect", "goal", "intend", "may", "objective", "plan", "predict", "potential", "positioned", "pioneer", "seek", "should", "target", "will", "would", and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the Company's business and the industry in which it operates and management's beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond its control. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Please see "Risk Factors" in the Company's annual information form dated March 11, 2026, and the risk factors included in our other public disclosure documents for a discussion of the material risk factors that could cause actual results to differ materially from the forward-looking information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

 
     Condensed Consolidated Interim Statement of Loss and 
                      Comprehensive Loss 
     (Expressed in thousands of Canadian dollars, except 
                      per share amounts) 
 
                     Three months ended   Nine months ended 
                           September 30      September 30 
                        2026     2025      2026      2025 
-----------------   --------   --------   -------   ------- 
Net revenue          237,994    244,219   669,666   693,902 
Cost of sales        180,108    180,042   502,619   505,483 
-------------------  -------   --------   -------   ------- 
Gross profit          57,886     64,177   167,047   188,419 
 
Investment income        927      1,777     3,472     6,162 
Share of profit 
 (loss) of 
 equity-accounted 
 investees             6,934       (234)    5,084    (4,387) 
 
General and 
 administrative       43,284     45,967   132,732   137,702 
Sales and marketing    3,462      3,617    11,136    10,768 
Depreciation and 
 amortization         12,659     12,928    38,145    39,076 
Share-based 
 compensation          1,767     10,883     5,033    15,190 
Restructuring costs      577      1,134     1,608     2,287 
Asset impairment, 
 net                  52,331      2,051    52,151     2,971 
Other income              --         --       (81)       -- 
Research and 
 development              --        156        12       354 
(Gain) loss on 
 disposition of 
 assets                  (16)        34       139       (54) 
-------------------  -------   --------   -------   ------- 
Operating loss       (48,317)   (11,050)  (65,272)  (18,100) 
 
Other expenses, net   (2,464)    (2,269)   (6,424)   (7,041) 
-------------------  -------   --------   -------   ------- 
Loss before income 
 tax                 (50,781)   (13,319)  (71,696)  (25,141) 
Income tax 
 (expense) 
 recovery                 (8)        --     3,174        -- 
-------------------  -------   --------   -------   ------- 
Net loss             (50,789)   (13,319)  (68,522)  (25,141) 
 
Equity-accounted 
 investees - share 
 of other 
 comprehensive 
 (loss) income           (29)     7,709    10,625   (13,250) 
Investments at fair 
 value through 
 other 
 comprehensive 
 income ("FVOCI") - 
 change in fair 
 value                 2,773     12,940     1,690     9,754 
-------------------  -------   --------   -------   ------- 
Comprehensive 
 (loss) income       (48,045)     7,330   (56,207)  (28,637) 
 
 
 
         Condensed Consolidated Interim Statement of Financial 
                                Position 
              (Expressed in thousands of Canadian dollars) 
 
As at                          September 30, 2026   December 31, 2025 
----------------------------  -------------------   ----------------- 
 
Assets 
Current assets 
   Cash and cash equivalents              132,479             252,243 
   Restricted cash                          8,162              20,081 
   Marketable securities                      139                  84 
   Accounts receivable                     31,734              27,643 
   Biological assets                        2,407               3,120 
   Inventory                              128,721             126,877 
   Prepaid expenses and 
    deposits                               16,614              15,566 
   Investments                                106                 484 
   Assets held for sale                       700                 746 
   Net investment in 
    subleases                               2,997               2,775 
-----------------------------  ------------------   ----------------- 
                                          324,059             449,619 
Non-current assets 
   Long-term deposits and 
    receivables                             2,457               4,526 
   Right of use assets                    131,608             138,353 
   Property, plant and 
    equipment                             139,376             151,900 
   Net investment in 
    subleases                               9,954              11,643 
   Intangible assets                       56,434              58,520 
   Investments                             17,314              11,574 
   Equity-accounted investees             467,730             385,534 
   Goodwill                                75,238             124,248 
-----------------------------  ------------------   ----------------- 
Total assets                            1,224,170           1,335,917 
-----------------------------  ------------------   ----------------- 
 
Liabilities 
Current liabilities 
   Accounts payable and 
    accrued liabilities                    46,902              56,747 
   Lease liabilities                       35,706              35,462 
                                           82,608              92,209 
Non-current liabilities 
   Lease liabilities                      126,614             134,471 
   Other liabilities                        7,753               8,041 
-----------------------------  ------------------   ----------------- 
Total liabilities                         216,975             234,721 
-----------------------------  ------------------   ----------------- 
 
Shareholders' equity 
   Share capital                        2,127,355           2,310,398 
   Warrants                                   306                 306 
   Contributed surplus                     53,377              54,038 
   Accumulated deficit                 (1,225,053)         (1,302,441) 
   Accumulated other 
    comprehensive income 
    ("AOCI")                               51,210              38,895 
-----------------------------  ------------------   ----------------- 
Total shareholders' equity              1,007,195           1,101,196 
-----------------------------  ------------------   ----------------- 
Total liabilities and 
 shareholders' equity                   1,224,170           1,335,917 
-----------------------------  ------------------   ----------------- 
 
 
 
       Condensed Consolidated Interim Statement of Cash Flows 
            (Expressed in thousands of Canadian dollars) 
 
                          Three months ended   Nine months ended 
                                September 30      September 30 
                             2026     2025       2026      2025 
----------------------   --------   --------   --------   ------- 
Cash provided by (used 
in): 
Operating activities 
   Net loss for the 
    period                (50,789)   (13,319)   (68,522)  (25,141) 
   Adjustments for: 
     Income tax expense 
      (recovery)                8         --     (3,174)       -- 
     Interest and fee 
      income                 (927)    (1,675)    (3,417)   (5,849) 
     Change in fair 
      value of 
      biological assets       585        180        594    (2,559) 
     Change in fair 
      value of inventory 
      sold                   (276)       349        249     1,313 
     Share-based 
      compensation          1,767     10,883      5,033    15,190 
     Depreciation and 
      amortization         13,893     13,972     41,998    42,108 
     (Gain) loss on 
      disposition of 
      assets                  (16)        34        139       (54) 
     Inventory 
      impairment and 
      obsolescence          3,455      1,833      6,057     2,663 
     Finance costs, net     1,951      1,812      6,007     5,149 
     Change in estimate 
      of fair value of 
      derivative 
      warrants                 --         (1)        --       (26) 
     Unrealized foreign 
      exchange loss 
      (gain)                  180       (153)      (832)       40 
     Transaction costs         --         --         10        -- 
     Asset impairment, 
      net                  52,331      2,051     52,151     2,971 
     Share of (profit) 
      loss of 
      equity-accounted 
      investees            (6,934)       234     (5,084)    4,387 
     Unrealized (gain) 
      on marketable 
      securities               --       (102)       (55)     (313) 
   Additions to 
    marketable 
    securities                 --         --        151       313 
   Income distributions 
    from 
    equity-accounted 
    investees                 315         --        315        68 
   Interest received          822      1,409      3,377     5,628 
   Exercise of 
    cash-settled 
    deferred share 
    units                      --         --       (474)       -- 
   Change in non-cash 
    working capital         2,185     14,194     (8,805)     (282) 
------------------------  -------   --------   --------   ------- 
Net cash provided by 
 operating activities      18,550     31,701     25,718    45,606 
------------------------  -------   --------   --------   ------- 
Investing activities 
   Additions to 
    property, plant and 
    equipment              (1,196)    (5,185)    (5,620)   (8,853) 
   Additions to 
    investments                --         --     (4,183)  (16,414) 
   Principal payments 
    from investments          121        129        359    27,293 
   Proceeds from 
    disposal of 
    investments                --     15,058         --    15,058 
   Capital 
    (contributions) 
    distributions from 
    equity-accounted 
    investees             (60,762)       481    (63,628)    4,273 
   Proceeds from 
    disposal of 
    property, plant and 
    equipment                 538         --      2,332       166 
   Acquisitions                --         --     (2,900)   (1,000) 
   Change in non-cash 
    working capital            75         39        712        10 
------------------------  -------   --------   --------   ------- 
Net cash (used in) 
 provided by investing 
 activities               (61,224)    10,522    (72,928)   20,533 
------------------------  -------   --------   --------   ------- 
Financing activities 
   Change in restricted 
    cash                   11,950         --     11,950        -- 
   Payments on lease 
    liabilities, net      (10,228)    (9,920)   (30,385)  (29,217) 
   Repurchase of common 
    shares                (10,042)        (3)   (43,113)  (15,034) 
   Change in non-cash 
    working capital           265         57      1,136       334 
------------------------  -------   --------   --------   ------- 
Net cash used in 
 financing activities      (8,055)    (9,866)   (60,412)  (43,917) 
------------------------  -------   --------   --------   ------- 
Change in cash and cash 
 equivalents              (50,729)    32,357   (107,622)   22,222 
Adjustment on initial 
 application of 
 amendments to IFRS 9 on 
 January 1, 2026               --         --    (12,142)       -- 
Cash and cash 
 equivalents, beginning 
 of period                183,208    208,224    252,243   218,359 
------------------------  -------   --------   --------   ------- 
Cash and cash 
 equivalents, end of 
 period                   132,479    240,581    132,479   240,581 
------------------------  -------   --------   --------   ------- 
 
 

NON-IFRS MEASURES

Certain specified financial measures in this news release are non-IFRS measures. These terms are not defined by IFRS and, therefore, may not be comparable to similar measures reported by other companies. These non-IFRS financial measures should not be considered in isolation or as an alternative for or superior to measures of performance prepared in accordance with IFRS. These measures are presented and described in order to provide shareholders and potential investors with additional measures in understanding the Company's operating results in the same manner as the management team.

ADJUSTED OPERATING INCOME (LOSS)

Adjusted operating income (loss) is a non-IFRS financial measure which the Company uses to evaluate its operating performance in a similar manner to its management team. The Company defines adjusted operating income (loss) as operating income (loss) less restructuring costs (recovery), goodwill and intangible asset impairments and asset impairments triggered by restructuring activities.

The following tables reconcile adjusted to un-adjusted operating income (loss) for the periods noted.

 
                    Cannabis   Cannabis    Cannabis   Liquor 
($000s)               Retail  Operations     Total    Retail  Investments  Corporate    Total 
-----------------  ---------  ----------   --------   ------  -----------  ---------   ------- 
Three months ended September 30, 2026 
---------------------------------------------------------------------------------------------- 
Operating income 
 (loss)                5,244     (64,693)   (59,449)   6,035        7,861     (2,764)  (48,317) 
Adjustments: 
   Restructuring 
    costs                 40         313        353        2           --        222       577 
   Goodwill and 
    intangible 
    asset 
    impairments           --      52,022     52,022       --           --         --    52,022 
   Impairments 
    triggered by 
    restructuring         --         967        967       --           --         --       967 
------------------  --------  ----------   --------   ------  -----------  ---------   ------- 
Adjusted operating 
 income (loss)         5,284     (11,391)    (6,107)   6,037        7,861     (2,542)    5,249 
------------------  --------  ----------   --------   ------  -----------  ---------   ------- 
 
 
                    Cannabis   Cannabis    Cannabis   Liquor 
($000s)               Retail  Operations     Total    Retail  Investments  Corporate    Total 
-----------------  ---------  ----------   --------   ------  -----------  ---------   ------- 
Nine months ended September 30, 2026 
---------------------------------------------------------------------------------------------- 
Operating income 
 (loss)                9,328     (80,836)   (71,508)   5,899        8,340     (8,003)  (65,272) 
Adjustments: 
   Restructuring 
    costs                 75         544        619      227           --        762     1,608 
   Goodwill and 
    intangible 
    asset 
    impairments           --      52,022     52,022       --           --         --    52,022 
   Impairments 
    triggered by 
    restructuring         --         967        967       --           --         --       967 
------------------  --------  ----------   --------   ------  -----------  ---------   ------- 
Adjusted operating 
 income (loss)         9,403     (27,303)   (17,900)   6,126        8,340     (7,241)  (10,675) 
------------------  --------  ----------   --------   ------  -----------  ---------   ------- 
 
 
                    Cannabis   Cannabis    Cannabis   Liquor 
($000s)               Retail  Operations     Total    Retail  Investments  Corporate    Total 
-----------------  ---------  ----------   --------   ------  -----------  ---------   ------- 
Three months ended September 30, 2025 
---------------------------------------------------------------------------------------------- 
Operating income 
 (loss)(1)             5,047     (10,882)    (5,835)   6,591        1,543    (13,349)  (11,050) 
Adjustments: 
   Restructuring 
    costs                 --         258        258       --           --        876     1,134 
   Impairments 
    triggered by 
    restructuring         --         404        404       --           --         --       404 
------------------  --------  ----------   --------   ------  -----------  ---------   ------- 
Adjusted operating 
 income (loss)         5,047     (10,220)    (5,173)   6,591        1,543    (12,473)   (9,512) 
------------------  --------  ----------   --------   ------  -----------  ---------   ------- 
                    Cannabis    Cannabis   Cannabis   Liquor 
($000s)               Retail  Operations      Total   Retail  Investments  Corporate     Total 
-----------------  ---------  ----------   --------   ------  -----------  ---------   ------- 
Nine months ended September 30, 2025 
---------------------------------------------------------------------------------------------- 
Operating income 
 (loss)(1)            10,557     (20,186)    (9,629)  10,884        1,775    (21,130)  (18,100) 
Adjustments: 
   Restructuring 
    costs                 --         828        828       --           --      1,459     2,287 
   Impairments 
    triggered by 
    restructuring         --       3,100      3,100       --           --         --     3,100 
------------------  --------  ----------   --------   ------  -----------  ---------   ------- 
Adjusted operating 
 income (loss)        10,557     (16,258)    (5,701)  10,884        1,775    (19,671)  (12,713) 
------------------  --------  ----------   --------   ------  -----------  ---------   ------- 
 
 

(4) In 2026, the Company began allocating applicable direct and indirect overhead costs from the corporate segment to each individual operating segment all categorized within general and administrative expenses. The Company has recast the comparative period to illustrate the impact of these allocations had they been done during the prior period.

GROSS MARGIN

Gross margin is a supplementary financial measure calculated as gross profit divided by net revenue for the periods presented. This measure evaluates the underlying profitability of our operations and provides useful information about the Company's ability to price products effectively, manage input costs, drive operating efficiencies, and compare results across periods and business segments

FREE CASH FLOW

Free cash flow is a non-IFRS financial measure which the Company uses to evaluate its financial performance, providing information which management believes to be useful in understanding and evaluating the Company's ability to generate positive cash flows as it removes cash used for non-operational items. The Company defines free cash flow as the total change in cash and cash equivalents less cash used for common share repurchases, dividends (if any), changes to debt instruments, changes to long-term investments, net cash used for acquisitions plus cash provided by dispositions (if any).

The following table reconciles free cash flow to change in cash and cash equivalents for the periods noted.

 
                     Three months ended   Nine months ended 
                           September 30      September 30 
($000s)                 2026     2025       2026      2025 
-----------------   --------   --------   --------   ------- 
Change in cash and 
 cash equivalents    (50,729)    32,357   (107,622)   22,222 
Adjustments: 
   Repurchase of 
    common shares     10,042          3     43,113    15,034 
   Changes to 
    long-term 
    investments       60,641    (15,668)    67,301   (30,523) 
   Acquisitions, 
    net of cash 
    acquired              --         --      2,900     1,000 
-------------------  -------   --------   --------   ------- 
Free cash flow        19,954     16,692      5,692     7,733 
-------------------  -------   --------   --------   ------- 
 
 

SAME-STORE SALES

Same-store sales is a non-IFRS financial measure which the Company uses to evaluate its financial performance in its retail segments. Same store sales provides information which management believes to be useful to investors, analysts and others in understanding and evaluating the Company's sales trends excluding the effect of the opening and closure of stores.

Same store sales refers to the revenue generated by the Company's existing retail locations during the current and prior comparison periods.

ADJUSTED EBITDA

Adjusted EBITDA is a non-IFRS financial measure which the Company uses to evaluate its operating performance. Adjusted EBITDA provides information to investors, analysts, and others to aid in understanding and evaluating the Company's operating results. The Company defines adjusted EBITDA as net earnings (loss) before inventory and biological assets fair value and impairment adjustments, share of (gain) loss of equity-accounted investees, depreciation and amortization, share-based compensation expense, restructuring costs, asset impairment, gain or loss on disposal of property, other expenses, net, income tax expense (recovery) and excluding non-recurring items including ERP implementation costs and litigation settlements, net of recoveries.

 
                        Three months ended   Nine months ended 
                              September 30      September 30 
($000s)                    2026     2025      2026      2025 
--------------------   --------   --------   -------   ------- 
Net earnings (loss)     (50,789)   (13,319)  (68,522)  (25,141) 
Adjustments: 
   Inventory and 
    biological assets 
    fair value and 
    impairment 
    adjustments           3,764      2,362     6,900     1,417 
   Share of loss 
    (profit) of 
    equity-accounted 
    investees            (6,934)       234    (5,084)    4,387 
   Depreciation and 
    amortization         12,659     12,928    38,145    39,076 
   Share-based 
    compensation          1,767     10,883     5,033    15,190 
   Restructuring costs      577      1,134     1,608     2,287 
   Asset (reversal) 
    impairment           52,331      2,051    52,151     2,971 
   Loss (gain) on 
    disposition of 
    PP&E                    (16)        34       139       (54) 
   Other expenses, net    2,464      2,269     6,424     7,041 
   Income tax recovery        8         --    (3,174)       -- 
   Non-recurring items      (15)      (501)      549      (696) 
----------------------  -------   --------   -------   ------- 
Adjusted EBITDA          15,816     18,075    34,169    46,478 
----------------------  -------   --------   -------   -- 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment